ORIGINAL ARTICLE: K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Mercredi 22 Octobre 2008 - 06:55 - 2 mois, 2 semaines depuis
-
Presse spécialisée
-
New England Journal of Medicin
This study examined the mutation status of the K-ras gene in colorectal tumors from patients who were enrolled in a trial of cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR). A survival benefit was found among patients with tumors bearing wild-type K-ras but not among patients with tumors bearing mutated K-ras. Wild-type K-ras is essential in transmitting signals initiated by EGFR.